See more : Jayjun Cosmetic Co., Ltd. (025620.KS) Income Statement Analysis – Financial Results
Complete financial analysis of SAMSUNG PHARM. Co., LTD. (001360.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SAMSUNG PHARM. Co., LTD., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sydinvest Aggressiv (SYVAUA.CO) Income Statement Analysis – Financial Results
- Shenzhen Yitoa Intelligent Control Co.,Ltd. (300131.SZ) Income Statement Analysis – Financial Results
- Magni-Tech Industries Berhad (7087.KL) Income Statement Analysis – Financial Results
- CHAPTERS Group AG (CHG.DE) Income Statement Analysis – Financial Results
- Reko International Group Inc. (RKIGF) Income Statement Analysis – Financial Results
SAMSUNG PHARM. Co., LTD. (001360.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sspharm.co.kr
About SAMSUNG PHARM. Co., LTD.
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, and others, as well as vitamins and energy drinks, and functional foods. The company was founded in 1929 and is based in Hwaseong-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.96B | 51.83B | 54.90B | 48.27B | 44.57B | 46.48B | 41.92B | 48.22B | 42.16B | 30.29B | 46.92B | 47.29B | 44.08B | 39.24B | 37.06B | 33.24B | 32.80B |
| Cost of Revenue | 28.98B | 27.21B | 45.62B | 37.82B | 35.17B | 37.89B | 36.84B | 40.61B | 30.89B | 21.79B | 29.52B | 28.15B | 26.13B | 22.62B | 22.43B | 19.62B | 19.58B |
| Gross Profit | 22.97B | 24.62B | 9.28B | 10.45B | 9.40B | 8.59B | 5.08B | 7.61B | 11.27B | 8.50B | 17.40B | 19.14B | 17.95B | 16.63B | 14.62B | 13.62B | 13.22B |
| Gross Profit Ratio | 44.22% | 47.50% | 16.91% | 21.65% | 21.09% | 18.48% | 12.12% | 15.78% | 26.73% | 28.06% | 37.08% | 40.47% | 40.71% | 42.37% | 39.46% | 40.98% | 40.31% |
| Research & Development | 2.28B | 327.02M | 650.54M | 663.58M | 90.93M | 377.51M | 938.79M | 926.54M | 296.67M | 5.83M | 3.00M | 55.00M | 74.00M | 289.18M | 34.32M | 50.67M | 95.31M |
| General & Administrative | 1.04B | 1.18B | 929.05M | 1.08B | 1.33B | 1.47B | 1.37B | 1.95B | 1.89B | 2.90B | 4.01B | 3.61B | 4.07B | 3.65B | 3.34B | 2.28B | 2.20B |
| Selling & Marketing | 32.29B | 31.50B | 19.52B | 9.71B | 3.48B | 4.07B | 2.24B | 6.88B | 4.42B | 1.29B | 3.28B | 4.96B | 2.50B | 1.50B | 1.70B | 1.76B | 3.70B |
| SG&A | 33.33B | 32.69B | 20.45B | 10.79B | 4.82B | 5.55B | 3.61B | 8.84B | 6.31B | 4.19B | 7.30B | 8.56B | 6.58B | 5.15B | 5.04B | 4.04B | 5.90B |
| Other Expenses | 5.40B | 5.57B | 6.32B | 8.80B | 9.71B | 7.45B | -1.76B | -4.86B | 2.25B | -1.45B | -4.37B | -420.40M | -175.63M | -1.41B | 2.57B | 77.14M | -657.89M |
| Operating Expenses | 41.01B | 38.58B | 27.42B | 20.25B | 14.62B | 13.37B | 11.96B | 17.20B | 13.14B | 28.32B | 28.82B | 18.60B | 17.49B | 14.36B | 14.37B | 11.58B | 13.58B |
| Cost & Expenses | 69.99B | 65.79B | 73.04B | 58.07B | 49.79B | 51.27B | 48.80B | 57.81B | 44.04B | 50.11B | 58.34B | 46.75B | 43.62B | 36.98B | 36.80B | 31.19B | 33.16B |
| Interest Income | 806.68M | 726.50M | 549.40M | 173.93M | 636.41M | 1.25B | 692.21M | 214.25M | 116.41M | 10.58M | 1.54M | 78.29M | 65.88M | 51.94M | 57.74M | 90.12M | 199.92M |
| Interest Expense | 73.37M | 111.09M | 506.88M | 2.09B | 707.58M | 1.36B | 2.59B | 3.50B | 3.02B | 1.49B | 2.71B | 3.33B | 2.09B | 1.82B | 1.56B | 1.69B | 1.60B |
| Depreciation & Amortization | 1.91B | 3.01B | 3.20B | 4.20B | 4.22B | 3.76B | 3.92B | 3.32B | 2.48B | 1.47B | 1.38B | 1.11B | 1.12B | 1.04B | 1.13B | 1.11B | 1.05B |
| EBITDA | -21.69B | -21.97B | -36.46B | -25.32B | 12.42B | 3.10B | -4.46B | -11.58B | 3.01B | -20.79B | -14.41B | 1.20B | 1.47B | 1.95B | 4.00B | 3.31B | 291.00M |
| EBITDA Ratio | -41.74% | -19.51% | -26.72% | -24.43% | -3.89% | 1.07% | -9.68% | -20.57% | 7.13% | -65.34% | -30.69% | 2.76% | 3.33% | 4.97% | 10.80% | 9.95% | 0.71% |
| Operating Income | -18.04B | -13.96B | -18.14B | -9.80B | -5.22B | -3.27B | -6.88B | -9.59B | -1.87B | -19.82B | -11.42B | 541.60M | 455.92M | 2.27B | 257.44M | 2.04B | -352.42M |
| Operating Income Ratio | -34.73% | -26.94% | -33.04% | -20.30% | -11.72% | -7.02% | -16.41% | -19.88% | -4.44% | -65.44% | -24.33% | 1.15% | 1.03% | 5.77% | 0.69% | 6.15% | -1.07% |
| Total Other Income/Expenses | -5.63B | -11.13B | -22.14B | -29.83B | 13.56B | 2.77B | -3.82B | -11.02B | 1.22B | -3.93B | -7.07B | -3.67B | -2.20B | -3.17B | 1.06B | -1.53B | -2.00B |
| Income Before Tax | -23.67B | -25.09B | -40.28B | -39.88B | 7.09B | -2.02B | -10.97B | -22.04B | -653.85M | -23.75B | -18.49B | -3.13B | -1.75B | -906.23M | 1.32B | 513.21M | -2.36B |
| Income Before Tax Ratio | -45.57% | -48.41% | -73.36% | -82.61% | 15.90% | -4.34% | -26.16% | -45.71% | -1.55% | -78.41% | -39.40% | -6.62% | -3.97% | -2.31% | 3.55% | 1.54% | -7.18% |
| Income Tax Expense | 1.14B | 11.86B | 22.40B | 23.89B | 201.66M | 59.55M | -3.69B | -424.06M | 340.54M | -1.44B | -4.36B | -342.10M | -109.74M | -1.35B | 2.62B | -121.00M | -462.80M |
| Net Income | -24.81B | -36.95B | -62.68B | -63.76B | 6.89B | -2.08B | -7.54B | -21.62B | -994.39M | -23.75B | -18.49B | -3.13B | -1.75B | -906.23M | 1.32B | 634.21M | -2.36B |
| Net Income Ratio | -47.76% | -71.29% | -114.17% | -132.10% | 15.45% | -4.47% | -17.99% | -44.83% | -2.36% | -78.41% | -39.40% | -6.62% | -3.97% | -2.31% | 3.55% | 1.91% | -7.18% |
| EPS | -333.83 | -496.74 | -852.31 | -941.87 | 106.06 | -40.51 | -172.88 | -603.70 | -33.28 | -1.11K | -1.42K | -332.00 | -197.65 | -102.42 | 148.50 | 71.69 | -266.28 |
| EPS Diluted | -333.83 | -496.74 | -852.31 | -941.87 | 106.06 | -40.51 | -172.88 | -603.70 | -33.28 | -1.11K | -1.42K | -332.00 | -197.65 | -102.42 | 148.50 | 71.69 | -266.28 |
| Weighted Avg Shares Out | 74.33M | 74.39M | 73.54M | 67.70M | 64.92M | 51.24M | 43.61M | 35.81M | 29.87M | 21.34M | 12.98M | 9.43M | 8.84M | 8.85M | 8.87M | 8.85M | 8.85M |
| Weighted Avg Shares Out (Dil) | 74.33M | 74.39M | 73.54M | 67.70M | 64.92M | 51.24M | 43.61M | 35.81M | 29.87M | 21.34M | 12.98M | 9.43M | 8.84M | 8.85M | 8.87M | 8.85M | 8.85M |
Source: https://incomestatements.info
Category: Stock Reports